1. Bioproduction solutions
Date
Name
Thank you for allowing us this opportunity to provide an overview of Life Technologies bioproduction platform. This presentation will give insight to how our products and services fit within the workflow of our customers.

2. from molecule to market Expression and Production
Setting new standards from molecule to market Introducing bioproduction solutions from Life Technologies
bioproduction solutions
from molecule to market
Cell
Therapy
Therapeutic
Protein Production
Microbial
Expression and Production
Viral
Vaccine
Production
The bio-production platform over the last 4 years has been focused on a molecule to market. As we look toward the future it is our mission to give you more choices and ways to improve your workflow as you move your molecules from early stage indications to Commercial launch.
This slide provides an understanding of the various served markets and Life’s expertise in the area of products and services that will optimize the workflow within each market. We have had a long term commitment and a documented track record of supporting Therapeutic Proteins, Microbial Expression and Viral Vaccines.
The fourth area of focus is within the Cell Therapy market. During 2010/2011 Life Technologies played a key role in supporting the launch of a prostate cancer treatment. As the Cell Therapy market continue to emerge, you will see various products and workflow initiatives from Life Tech to support the growing demands within this market segment
NOTE TO PRESENTER: The appendix contains lists of products and services and links to their online pages.
About us
Why us?
Working with us
Products and services
Summary

3. from molecule to market Expression and Production
Setting new standards from molecule to market Introducing bioproduction solutions from Life Technologies
bioproduction solutions
from molecule to market
Cell
Therapy
Therapeutic
Protein Production
Microbial
Expression and Production
Viral
Vaccine
Production
NOTE TO PRESENTER: DO NOT DELETE THIS PAGE.
This is a hidden page - it is the link to the “home” button from subsequent pages, so the viewer/presenter does not have to go through the animation every time they go “home”.
About us
Why us?
Working with us
Products and services
Summary

4. PRESENTER IMPORTANT: You have several options on how to show this video.
1. As part of this slide deck
This video should play automatically as part of the slide deck if saved in the same folder as the Powerpoint deck.
2. As a stand-alone video separate from this deck
From YouTube: go to
From your computer: Download the high-res version (75MB) from Documentum at 4

5. Life Technologies is a global biotechnology leader dedicated to making life even better
160+ Countries served
$3.6B global leader
1B$ Revenue in Pharma / Biotech space
300M$ Revenue in Diagnostics space
customers
50,000 + products
3,900+ patents and licenses
10,000 employees
>1,000 New Product Introductions per year
Industry recognition as a life science leader
As we introduce the BioProduction business it's helpful to understand where the we fit within Life Technologies.
Life Technologies view the industry in three segments. The research market, which focuses on PCR and Sequencing and Cell Systems. This is our Research and Discovery segment and represents approx 70% of our business.
The commercial applications market is also referred to the regulated market. It includes bioproduction of which we will talk in more detail in later slides…But it also includes applied markets segments like forensics, food testing, animal health, and agriculture/biology.
Our forensic team are the market leaders within this business segments working with our the armed forces and the various law enforcement teams around the world. They have been instrumental in supporting crime lab and other security measures on a global level.
In the food testing side of the business, we work not only with U.S. based operations, but as an example, we were instrumental in ensuring the safety of the food that was used in the Beijing Olympics. The Applied market represents approx 20-30% of Life Tech Rev.
An emerging horizon for us is on the clinical side. This is where we are focused on molecular diagnostics, genomics, and regenerative medicine. The goal here is to support therapeutic application by helping the developer of the drug to better understand the intended patient population. The positive implications is that it would allow the drug to reach its intented market and to reduced the risk of adverse impact on other patient population.
We are serving about 160 countries.
We're about $3.6 billion in annual sales.
We serve about 75,000 customers, 50,000 products.
We have about 3,900 patents and the significance of this data is that it demonstrate that we are a science driven company and not just simply a manufacturer of products.
LifeTechnologies.com

6. 27.2
Bioproduction is leading positive transformation in biologics production
Gibco®
Cell Culture
POROS®
Chromatography
Applied Biosystems®
SEQ Analytics
Cellular
Medicine
Leader in mAb polish chromatography
Leader in contaminant and impurity testing
New solutions for cell therapy, regenerative medicine
Leader in media and feeds for 50 years
Bioproduction
24 of the Top 25* pharmaceutical companies worldwide use a LIFE bioproduction solution, many with multi-site adoptions
A majority of future biotherapeutics currently in Phase 1-3 development use a LIFE bioproduction solution**
A large number of launched biotherapeutics today are manufactured using a LIFE bioproduction solution***
We are a market leader in this space
The Gibco Cell Culture business- celebrating 50 years of success via the support of the both the research and commercial markets. GIBCO is a solutions driven brand.
The POROS Chromatography Business is emerging as the leading collaborative supplier in the polished and capture step
The Analytics Business - Situated both in the assay development segment to process development and commercial application. The detection systems have been developed to look at both viral contaminants and impurities that are associated with biological manufacturing, both in microbial and also in mammalian cell culture.
Cellular medicine. Cell therapy and regenerative medicine are emerging segment markets that is attempting to gain traction and as mentioned earlier, back in 2010 a prostate cancer drug was introduced into the market via cell therapy technologies, and Life Technologies was instrumental doing this, in supporting that in the bioproduction space.
Life Tech BioProduction
Support 24 of the top 25 biopharmaceutical companies that are in the market.
We have a major focus towards Phase I to Phase III development
we understand the critical nature of deliverables throughout the process
We believe that we are the industry leader in the supporting the commercial manufacture of drugs
NOTES FOR PRESENTER:
2010 Top 25 Pharma
Pfizer (New York, New York)
Novartis (Basel, Switzerland)
Sanofi-Aventis (Paris, France)
Merck (Whitehouse Station, New Jersey)
Roche (Basel, Switzerland)
GlaxoSmithKline (Brentford, England)
AstraZeneca (London, England)
Johnson & Johnson (New Brunswick, New Jersey)
Eli Lilly (Indianapolis, Indiana)
Abbott (Abbott Park, Illinois)
Bristol-Myers Squibb (New York)
Teva (Petach Tikva, Israel)
Amgen (Thousand Oaks, California)
Bayer (Leverkusen, Germany)
Takeda (Osaka, Japan)
Boehringer Ingelheim (Ingelheim, Germany)
Novo Nordisk (Bagsvaerd, Norway)
Astellas (Tokyo, Japan)
Daiichi Sankyo (Tokyo, Japan)
Eisai (Tokyo, Japan)
Merck KGaA (Darmstadt, Germany)
Gilead Sciences (Foster City, California)
Baxter International (Deerfield, Illinois)
Mylan (Canonsburg, Pennsylvania) – no LIFE BP solution as of July 2011
Servier (Neuilly-sur-Seine)
* Based on list of Top 50 companies from PharmExec 50, Pharmaceutical Executive Magazine, May 2011
** Based on analysis using the Pharmaprojects Database - Pharmaceutical Research & Development Pipeline Intelligence, © Informa UK Ltd
***Based on analysis of list of Top 200 Pharmaceutical Products, The Njardarson Group, Cornell University

7. Bioproduction solutions are used by small to large companies across six continents
Designed for Phase 1-3
process development
to large-scale manufacturing
The BioProduction Business is clearly globally deployed with a diverse revenue and custom distribution
On the left pie chart, you'll see that about
31% of our customers are located in Europe
34% of our customers inside of the U.S.
The balance are in Asia-Pacific and Japan.
We have a strong interest in serving the emerging markets and we are seeing significant growth within those markets
The take home message is we understand that this is a global market and we have a global footprint to support your needs regardless of which markets you decide to serve.
On the right hand side of the slide, it gives you a sense of where our revenue is generated by customer segment.
As outlined in the pie chart
57% of our business comes from the large bio-pharma
14% of our business comes from mid-biotech/bio-pharma
16% from contract services
11% from Animal Health.
A couple of takeaways from this slide as it relates to who we support:
We understand that in many cases, technologies and processes will transfer. So a small to mid-biotech company will oftentimes license that technology to a large biopharma. We want our customers to be comfortable that we have a presence almost anywhere around the world and that we can support that interest regardless of whether it's in an emerging market or in some of the more established markets
Revenue, by Geography
Revenue, by Customer Segment

8. Solutions respond to urgent industry trends
Vaccines
Shift from egg-based to cell culture-based
Biosimilars
More drugs coming off patent, need for shorter time to end-user
Cells, Media
Standardization of cell lines, demand for shorter timelines, final product quality, higher titers
Product safety
Heightened concerns and risk of contamination
Purification bottlenecks
Need to support faster scale-up and manufacturing
Cell therapy
Need for complete workflow solutions
Ease of use
Major shift to disposables in upstream/downstream, automation for analytics
We understand the dynamics and the urgency of markets trends
Vaccine- both at a potential pandemic response and or a work flow improvement from egg based production to cell culture we serve as a key collaborative supporter within this market.
Biosimilars- As certain key drugs are coming off patent interest in the introduction of biosimilars clearly is an emerging business trend….where both the companies who own the patent and those who are seeking to enter the market are putting together their mutual game plan…We have coordinated effort in working with companies around that arena.
Cell & Media- we understand product quality, a cell line stability, and/or short-term or long-term demands that are needed within that market. Because we work throughout the continuum of both pre-clinical all the way through critical Phase III trials, we sensitive to the critical needs and the impact on the supply chain.
Product safety- whether raw material qualification and or the detection and or removal of contaminants that could work its way into a particular platform… We are geared both on the raw material screening side, on the finished goods side using our
Purification- whether if is managing a specific step in the process and or dealing with increase titers

9. Innovations transform bioproduction today
GMP cells
Friendly IP
Highest resolution + capacity
Impurity testing in < 5 hours
Freedom™ CHO Cell Lines
Simplified commercial cell line development
with optimized workflows and
unprecedented IP access
Three Areas of INNOATION
CHO Cell line.
We recognized when it came down to customers use of particular cell systems, that there were market constraints at both the development and transition to commercial manufacture of their therapeutic. Our objective was to address that need by the introduction of the Cho Kit.
This is a cGMP certified cell line that allows customers the freedom to operate from preclinical to launch of the therapeutic.
POROS XS- is formulated address increase titer, higher concentration of NaCl and broader pH ramge within the downstream purification polishing step
It has experienced one of the fastest adoption rates of any resin that we have introduced to the market so far.
In the last year and a half we have been adopted in a number of phase three clinical trials,
Residual DNA – using our realtime QPCR technology with focus on Host Cell and Protein A DNA detection. The objective is to provide our Customers with the most creditable set of data within the shortest turnaround time.
NOTE TO PRESENTER:
These are examples of how Bioproduction is setting new standards in how biologics are produced today.
Buttons are hyperlinked to the product lists for each of the businesses.
<Note: swap in the imagery or ad for a particular product or service to customize the slide to the needs of the audience.>
POROS® XS Chromatography Resin
High Resolution + High Capacity = Improved Yield
resDNASEQ® Host Cell DNA Quantitation System
Same-day results using integrated sample prep, reagents, instruments, and software
Gibco® Cell Culture
POROS® Chromatography
Applied Biosystems® SEQ Analytics
Cellular Medicine

10. Working with us Bioproduction Online Community You
LIFE Bioproduction homepage
Gibco Media Configurator for web quoting, order tracking
Webinars and educational events
Mobile applications
You
Gibco® Bioproduction Services
Gibco® Process Development Team
Scientific and business development support
Gibco® Program Management Office
Singlepoint of contact for order management and execution
Gibco® PD-Direct Services
Cell line development services
Media development and analytical services
Gibco® Media Express
Gibco® cGMP Media Custom Services
Account
Representative
How do we interact with our customer base.
We us a Business to Business approach, connecting
Process Science Fellows with our Customer Process Development team
Our Planners and PMO team with our Customer’s Supply Chain managers and Planners
Sr Executive Projects that are managed and updated via QBRs to insure our mutual ongoing support
Technical Support and Services
On-site technical support
POROS® Customs Services
SEQ Validation and Implementation Services
Cell therapy and stem cell services
Global Support 10

11. Bioproduction Manufacturing Sites
Worldwide distribution, service and support reach 150 countries on 6 continents
Bioproduction Manufacturing Sites
Grand Island, NY, United States
Cell culture media, reagents, and sera manufacturing
Auckland, New Zealand Sera and protein products manufacturing
Newcastle, Australia
Sera manufacturing
Singapore
Sequencing and PCR instrument
manufacturing
Austin, TX, United States
Pharma analytics kit manufacturing
Paisley, Scotland
Cell culture media and reagents
Christchurch, New Zealand
Protein products manufacturing
Bedford, MA, United States
Chromatography resins manufacturing
Warrington, England

12. Take a molecular leap into the future.
Let us take you from molecule to market, so you can take the world from today to tomorrow.
Meet new challenges
Escalating demand for biotherapeutics and vaccines
New cell lines
Heightened concerns about product safety
Emerging biosimilars
Personalized medicine
across multiple therapy classes
Therapeutic protein production
Microbial expression and production
Viral vaccines production
Regenerative medicine
Immunotherapy
using trusted brands
Gibco® cell culture
POROS® chromatography resins
Applied Biosystems® SEQ analytics
Cellular medicine solutions
that set new industry standards
Product quality
Product safety
Fast-to-market efficiency
Dedicated Program Management Office
bioproduction solutions
from molecule to market

13. Redefining bioproduction tomorrow
Today
Functional feeds
Segment-specific products and services (vaccines, biosimilars, CMOs, cell therapy)
Omics-based profiling
Affinity, IEX and custom chromatography
Protein PCR
Bioburden surveillance
Objectionable organism panels
Environmental monitoring programs
Next generation sequencing applications
Closed automated platform for cell isolation
GMP cell line kits
Media and feeds
Sera and reagents
Contaminant and impurity assays
Chromatography resins
Services
Take a molecular leap into the future with Bioproduction – your partner of choice today and into tomorrow.

14. Your partner from molecule to market Focus on both the journey and the destination2
Media optimization
Process optimization
Upstream, downstream and analytical solutions for every stage of the journey 1
Cell line development
Expression development 6
Global manufacturing 3
Cell expansion
Fermentation
Viral expansion
Getting from molecule to market occurs through six major steps. Clearly every customer is different. We want to show a general overview here to lay the foundation for the next slides which go through these steps in the context of the kind of therapeutic being produced. 5 4
Commercial
scale-up and launch
Clinical
manufacturing 14 14

15. Molecule-to-market solutions supporting mammalian therapeutic protein production
NEEDS
GMP CHO cell lines
Reproducible high titer
Rapid assays for key contaminants and impurities
Chemically defined, AOF media and matched feeds
High capacity, high resolution, salt-tolerant resins for polish chromatography
BIOPRODUCTION SOLUTIONS
Freedom™ CHO cell line kits
Gibco® PD-Direct cell line development services
POROS® analytical columns
MycoSEQ™ Mycoplasma Detection System
ViralSEQ® Virus Detection Assays (MMV, Vesivirus)
MicroSEQ® Microbial Identification System
Gibco® media and feeds
Custom cell culture media
Gibco® PD-Direct media development and analytical services
POROS® analytical columns
GoPure™ disposable columns
ViralSEQ® Virus Detection Assays (MMV, Vesivirus, PCV1/PCV2)
POROS® polish and capture chromatography resins
GoPure™ disposable columns
resDNASEQ® Host Cell DNA Quantitation Assays (CHO,NS0)
ProteinSEQ™ Quantitation Assay (Protein A, HCP)
MicroSEQ® Microbial Identification System for bacteria and fungi
Freedom™ CHO-S™
cell line kit
Gibco® media and feeds
POROS® Chromatography
Resins
MicroSEQ™ Microbial Identification System

16. Identification System
Molecule-to-market solutions supporting microbial expression and production
NEEDS
Host cell lines
Chemically defined media and vectors
Validated and automated rapid contaminant and impurity tests
High capacity, high resolution, salt-tolerant resins for polish chromatography
BIOPRODUCTION SOLUTIONS
POROS® analytical columns
MicroSEQ® Microbial Identification System
Custom media in different formats
POROS® chromatography resins
resDNASEQ® Host Cell DNA Quantitation Assays (e. coli, Pichia)
GoPure™ disposable columns
MicroSEQ® Microbial Identification System for bacteria and fungi
POROS® analytical
columns
resDNASEQ® Host Cell DNA Quantitation Assays
MicroSEQ® Microbial
Identification System

17. Molecule-to-market solutions supporting viral vaccine production
NEEDS
Integrated platform for top human and veterinary vaccine host cells
High cell density, virus titer, and virus stability
BIOPRODUCTION SOLUTIONS
Gibco® media development
and analytical services
resDNASEQ® Host Cell DNA Quantitation Assays
ViralSEQ® Virus Detection Assays
MicroSEQ® Microbial
Identification System
ViralSEQ® Virus Detection Assays (MMV, Vesivirus)
Gibco® PD-Direct media development and analytical services
MicroSEQ® Microbial Identification System
Gibco® media
Custom media in different formats
GoPure™ disposable columns
ViralSEQ® Virus Detection Assays (MMV, Vesivirus)
Gibco® PD-Direct media development and analytical services
MicroSEQ® Microbial Identification System
POROS® chromatography resins
resDNASEQ® Host Cell DNA Quantitation Assays (Vero, MDCK)
MicroSEQ® Microbial Identification System for bacteria and fungi

18. Molecule-to-market solutions supporting cell therapy
NEEDS
Integrated automated platforms
Efficient cell analytics
Custom solutions
High quality growth
BIOPRODUCTION SOLUTIONS
MycoSEQ™ Mycoplasma Detection System
MicroSEQ® Microbial Identification System
Dynabeads® lgG1 Binder CTS
DynaMag™ CTS magnet
Cell therapy and stem cell services
MicroSEQ® Microbial Identification System
Dynabeads® CD3/CD28 CTS
Media, growth factors, buffers and supplements
Cell therapy and stem cell services
MicroSEQ® Microbial Identification System for bacteria and fungi
MycoSEQ™ Mycoplasma
DetectionSystem
Cell therapy and
stem cell services
Dynabeads®
immunotherapy products

19. Legal Disclosure
Life Technologies manufactures products labeled for Research Use Only, and for In-Vitro Diagnostic use. Please refer to the Life Technologies website for specific indications and use information for these products.
© 2011 Life Technologies Corporation. All rights reserved.
The trademarks mentioned herein are the property of Life Technologies Corporation or their respective owners.

20. Appendix

21. Gibco® products and services
Media & feeds
Cells
CD CHO*
CD OptiCHO™*
CD FortiCHO™*
CHO CD EfficientFeed™ A
CHO CD EfficientFeed™ B*
CD EfficientFeed™ C AGT
Custom media in different formats (AGT, DPM, liquid, concentrate)
*Also available in proprietary Advanced Granulation Technology™ (AGT™) format
Freedom™ Cell Line Development Kits
CHO-S™
CHO-DG 44
Licensing
Sera
Reagents & disposables
Bioproduction services
Fetal bovine sera
Horse sera
Rabit sera
rHu Insulin AOF
Buffers
TryPLE™ Reagents
FoamAway™ anti-foaming agents
Gibco® disposable bags
Gibco® Process Development Team
Scientific and business development
Gibco® Program Management Office
Order execution and management
Gibco® PD-Direct Services
Cell line development services
Media development and analytical services
Gibco® Media Express
Gibco® cGMP Media Custom Services
“Great all around selection of products, great customer service.”
Customer survey, 2011

22. POROS® products and services
Bulk resins
Analytical columns
Disposable columns
XS 50 µm Bulk Resin
MabCapture™ A Resin
Heparin 50 µm Bulk Resin
HQ 50 µm Bulk Resin
HS 50 µm Bulk Resin
D 50 µm Bulk Resin
PI 50 µm Bulk Resin
R1 50 µm Bulk Resin
R2 50 µm Bulk Resin
Protein A 20 µm Columns, PEEK™
Protein G 20 µm Columns, PEEK™
AL 20 µm Columns, PEEK™
EP 20 µm Columns, PEEK™
OH 20 µm Columns, PEEK™
PI 20 µm Columns, PEEK™
HS 20 µm Columns, PEEK™
S 20 µm Columns, PEEK™
MC 20 µm Columns, PEEK™
HP 20 µm Columns, PEEK™
R1 20 µm Columns, PEEK™
R2 20 µm Columns, PEEK™
GoPure™ 1.2 cm Diameter Column
GoPure™ 8.0 cm Diameter Column
GoPure™ 20 cm Diameter Column
Services
Custom Services
“Their resins can be used at higher flow rates with very good protein binding capacity.”
Customer survey, 2011

23. Applied Biosystems® SEQ products and services
Product safety microbiological contaminant analysis
Product quality
biologics impurity analysis
Microbial Identification System
MicroSEQ® Rapid Sample Prep
PrepMan® Ultra Sample Prep. Reagent
Kits
MicroSEQ® S rDNA Bacterial Identification Kit
MicroSEQ® Full Gene 16S rDNA Bacterial Identification Kit
MicroSEQ® D2 LSU rDNA Fungal Identification Kit
Instruments
Veriti® 96-Well Thermal Cycler
3500 Genetic Analyzer
Software
MicroSEQ® iD Analysis Software
Services
Validation and Implementation Services
Mycoplasma Detection
MycoSEQ™ Mycoplasma Detection Assay
Host Cell Residual DNA Quantitation
resDNASEQ® Quantitative DNA System (CHO, NS0, E. coli, Pichia, MDCK, Vero)
Virus Detection
ViralSEQ® Vesivirus Detection Assay
ViralSEQ® MMV Detection Assay
Protein Detection
ProteinSEQ™ Protein Quantitation Assay
Sample Preparation
PrepSEQ® Mycoplasma Sample Preparation Kit plus Module M
PrepSEQ® Nucleic Acid Extraction Kit
7500 Fast Real-Time PCR System
Automate Express™ Nucleic Acid Extraction System
AccuSEQ® Real-Time PCR Detection Software
Implementation and Training Services
“Applied Biosystems® gives the most consistent results, and they have the best technical support for their products”
Customer survey, 2011

24. Cellular medicine products and services
Immunotherapy products
Stem cell media and reagents
AIM V® Medium CTS™
OpTmizer™ CTS™ T-Cell Expansion SFM
Dynabeads® CD3⁄CD28 CTS™
DynaMag™ CTS™
Cell Therapy Systems DPBS CTS™ (without Ca and Mg)
Recombinant human growth factors
Cell therapy and stem cell services
KnockOut™ CTS™ Media
CELLstart™ CTS™ Reagents
DPBS CTS™ Reagents (with Ca and Mg)
TrypLE™ Select CTS™ Reagents
GlutaMAX™-I CTS™ Reagents

25. Core strengths align with customer needs
Best-in-class technology
Global technical & sales support
Customer satisfaction
State-of-the-art operations
“They go all the way to cut red tape and deliver what you need today and not tomorrow .“
“You can trust this company.”
Customer survey, 2011